- The Annual Meeting of the Thai Gynecologic Cancer Society 2019: Meeting report
-
Charoenkwan K, Srisomboon J
- KMID: 2458914
- J Gynecol Oncol.
- 2019 Nov;30(6):e118.
- doi: 10.3802/jgo.2019.30.e118
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
-
Zang R, Zhu J
- KMID: 2458912
- J Gynecol Oncol.
- 2019 Nov;30(6):e116.
- doi: 10.3802/jgo.2019.30.e116
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
-
Tewari KS
- KMID: 2458915
- J Gynecol Oncol.
- 2019 Nov;30(6):e119.
- doi: 10.3802/jgo.2019.30.e119
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Reviewer recognition in 2019
-
Editorial Office of the Journal of Gynecologic Oncology
- KMID: 2458906
- J Gynecol Oncol.
- 2019 Nov;30(6):e110.
- doi: 10.3802/jgo.2019.30.e110
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO)
-
Yoshihara , Sekine M, Nishino K, Enomoto T
- KMID: 2458910
- J Gynecol Oncol.
- 2019 Nov;30(6):e114.
- doi: 10.3802/jgo.2019.30.e114
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- ASGO, KSGO, and JSGO announce collaboration
-
Editorial Office of the Journal of Gynecologic Oncology
- KMID: 2458911
- J Gynecol Oncol.
- 2019 Nov;30(6):e115.
- doi: 10.3802/jgo.2019.30.e115
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
-
Machida H, Matsuo K, Enomoto T, Mikami M
- KMID: 2458909
- J Gynecol Oncol.
- 2019 Nov;30(6):e113.
- doi: 10.3802/jgo.2019.30.e113
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy
-
Ushijima K
- KMID: 2458913
- J Gynecol Oncol.
- 2019 Nov;30(6):e117.
- doi: 10.3802/jgo.2019.30.e117
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
-
Batista TP, Kusamura S
- KMID: 2458907
- J Gynecol Oncol.
- 2019 Nov;30(6):e111.
- doi: 10.3802/jgo.2019.30.e111
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
-
Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG, on behalf of KGOG investigators
- KMID: 2458908
- J Gynecol Oncol.
- 2019 Nov;30(6):e112.
- doi: 10.3802/jgo.2019.30.e112
BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed... -
- CITED
-
- Close
- SHARE
-
- Close
- Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
-
Indini A, Di Guardo , Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M
- KMID: 2458899
- J Gynecol Oncol.
- 2019 Nov;30(6):e94.
- doi: 10.3802/jgo.2019.30.e94
OBJECTIVE: immunotherapy with immune checkpoint inhibitors has become one of the standard therapeutic modalities for patients with advanced melanoma. Melanoma of the female lower genital tract is a rare and... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
-
Chambers L, Son J, Radeva M, DeBernardo R
- KMID: 2458898
- J Gynecol Oncol.
- 2019 Nov;30(6):e93.
- doi: 10.3802/jgo.2019.30.e93
OBJECTIVE: To identify factors associated with non-completion of intraperitoneal with intravenous chemotherapy [IP/IV] in women with epithelial ovarian cancer (EOC). METHODS: This was an Institutional Review Board approved, retrospective cohort study... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
-
Cheng H, Huo L, Wang D, Xiang Y
- KMID: 2458902
- J Gynecol Oncol.
- 2019 Nov;30(6):e99.
- doi: 10.3802/jgo.2019.30.e99
OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma
-
Yoshida K, Yoshikawa , Shirakawa , Niimi K, Suzuki S, Kajiyama H, Kikkawa F
- KMID: 2458894
- J Gynecol Oncol.
- 2019 Nov;30(6):e85.
- doi: 10.3802/jgo.2019.30.e85
OBJECTIVES: There is increasing evidence that systemic inflammatory response (SIR) markers are prognostic factors for various types of cancers. This is the first study to evaluate the usefulness of SIR... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan
-
Matsumoto , Shimokawa , Nasu K, Shikama A, Shiozaki T, Futagami M, Kai K, Nagano H, Mori T, Yano M, Sugino N, Fujimoto E, Yoshioka N, Nakagawa S, Shimada M, Tokunaga H, Yamada Y, Tsuruta T, Tasaki K, Nishikawa , Kuji S, Motohashi , Ito K, Yamada T, Teramoto N
- KMID: 2458905
- J Gynecol Oncol.
- 2019 Nov;30(6):e103.
- doi: 10.3802/jgo.2019.30.e103
OBJECTIVE: We conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings... -
- CITED
-
- Close
- SHARE
-
- Close
- Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors
-
Park JY, Lee SH, Kim KR, Kim YT, Nam JH
- KMID: 2458900
- J Gynecol Oncol.
- 2019 Nov;30(6):e95.
- doi: 10.3802/jgo.2019.30.e95
OBJECTIVE: To determine the accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade in patients with mucinous ovarian tumors. METHODS: This study included 1,032 patients with mucinous... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis
-
Yoshihara , Kajiyama H, Tamauchi S, Suzuki S, Takahashi , Matsui S, Kikkawa F
- KMID: 2458904
- J Gynecol Oncol.
- 2019 Nov;30(6):e102.
- doi: 10.3802/jgo.2019.30.e102
OBJECTIVE: The aim of this study was to investigate the clinical characteristics of young patients with stage I clear-cell carcinoma (CCC) and evaluate the prognostic factors and effects of fertility-sparing... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients
-
So M, Miyamoto T, Murakami R, Abiko K, Hamanishi , Baba T, Mandai M
- KMID: 2458903
- J Gynecol Oncol.
- 2019 Nov;30(6):e100.
- doi: 10.3802/jgo.2019.30.e100
OBJECTIVE: In patients with recurrent ovarian cancer (ROC) in whom surgery is likely to render them disease-free, it is unclear whether secondary cytoreductive surgery (SCS) combined with chemotherapy is superior... -
- CITED
-
- Close
- SHARE
-
- Close
- The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
-
Han KH, Park NH, Kim JJ, Kim S, Kim HS, Lee M, Song YS
- KMID: 2458893
- J Gynecol Oncol.
- 2019 Nov;30(6):e83.
- doi: 10.3802/jgo.2019.30.e83
OBJECTIVE: To identify the power of tumor markers for predicting ovarian cancer according to menopausal status. METHODS: The medical records of 876 women with ovarian cysts were retrospectively reviewed. Cancer antigen... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
-
Mitsuhashi A, Habu Y, Kobayashi , Kawarai Y, Ishikawa H, Usui H, Shozu M
- KMID: 2458897
- J Gynecol Oncol.
- 2019 Nov;30(6):e90.
- doi: 10.3802/jgo.2019.30.e90
OBJECTIVE: The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
